Drugs / PPV23
PPV23
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00153543 | May 2002 → Jun 2003 | pneumococcal infection | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT03069703 | Feb 2018 → Nov 2020 | pneumococcal infection | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT02717494 | Mar 2016 → Nov 2018 | congenital human immunodeficiency virus | Westat | Completed | Missed primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT02285036 | Sep → Dec 2012 | pneumococcal infection | Walvax Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT05298800 | Oct 2021 → Dec 2022 | — | Centers for Disease Control and Prevention, China | Unknown | No outcome recorded |
| Phase 4 | NCT05079152 | May 2021 | influenza, streptococcal pneumonia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT04790851 | Mar → Sep 2021 | COVID-19, influenza, streptococcal pneumonia | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT04559204 | Sep → Nov 2020 | influenza, streptococcal pneumonia | China National Biotec Group Company Limited | Completed | No outcome recorded |
| Phase 4 | NCT02637583 | Oct 2017 → Nov 2022 | pneumococcal infection | Jena University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03041051 | Dec 2015 → Mar 2017 | HIV infectious disease | Aghia Sophia Children's Hospital of Athens | Unknown | No outcome recorded |
| Phase 4 | NCT02492438 | Feb 2013 → Feb 2014 | chronic renal failure syndrome | AZ Sint-Jan AV | Completed | No outcome recorded |
| Comparator or background therapy9 trials | ||||||
| Phase 0 | NCT07025876 Comparator | Nov 2023 → Jun 2024 | streptococcal pneumonia | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 0 | NCT02515240 Comparator | Jul 2010 → Jun 2014 | pneumococcal infection | University of Toledo Health Science Campus | Completed | No outcome recorded |
| Phase 1 | NCT06056050 Comparator | Dec 2023 → Apr 2024 overdue | diphtheria, pertussis, tetanus | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05622942 Comparator | Mar → Sep 2023 | pneumonia | CanSino Biologics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT07035054 Comparator | Apr → Nov 2024 | streptococcal pneumonia | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/3 | NCT06708286 Comparator | Dec 2024 → May 2025 overdue | diphtheria, pertussis, tetanus | CanSino Biologics Inc. | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05480436 Comparator | Aug 2022 → Jan 2023 | COVID-19, hemolytic anemia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
| Phase 4 | NCT04974294 Comparator | Jul 2021 → Jul 2023 | streptococcal pneumonia | Liverpool School of Tropical Medicine | Unknown | No outcome recorded |
| — | NCT02726347 Comparator | Apr 2016 → Apr 2018 | asthma | National Jewish Health | Unknown | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPV-23 | “a third booster dose of SARS-CoV-2 inactivated vaccine (CoronaVac), inactivated quadrivalent influenza vaccine (IIV4), and 23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 39229259 ↗ Aug 202420“PPV23 produced by Chengdu Institute of Biological Products is a formulation with each vial containing 0.5 ml, and the dosage is 0.5 ml per person per administration.” NCT07035054 ↗ “A 23-valent pneumococcal polysaccharide vaccine (PPV-23) has been licensed in the United States since 1983” NCT00153543 ↗ |
| Known as | 23-valent pneumococcal polysaccharide vaccine | “an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine” PMID 35931636 ↗ Jul 20224“The 23-valent pneumococcal polysaccharide vaccine (PPV23) produced by Chengdu Institute of Biological Products” NCT07025876 ↗ “A 23-valent pneumococcal polysaccharide vaccine (PPV-23) has been licensed in the United States since 1983” NCT00153543 ↗ “23-valent pneumococcal polysaccharide vaccine (PPV23)” NCT04559204 ↗ “23-valent pneumococcal polysaccharide vaccine (PPV23)” PMID 29722823 ↗ Jun 2018 |
| Known as | 23-Valent Pneumococcal Polysaccharide Vaccine（PPV23） | “23-valent Pneumococcal Polysaccharide Vaccine (PPV23)” NCT06708286 ↗1“23-Valent Pneumococcal Polysaccharide Vaccine（PPV23）” NCT06056050 ↗ |
| Known as | PneumovaxR | “In a prospective study, serological responses and opsonic activity towards Streptococcus pneumoniae were measured in 60 HIV-infected patients and 25 controls after the...” PMID 8580899 ↗ Sep 1995 |
| Modality | Vaccine | “23-valent pneumococcal polysaccharide vaccine” NCT00153543 ↗ |
| Route | Intramuscular | “sterile, liquid vaccine for intramuscular or subcutaneous injection” NCT02285036 ↗ |
| Route | Subcutaneous | “sterile, liquid vaccine for intramuscular or subcutaneous injection” NCT02285036 ↗ |